PHILADELPHIA, Dec. 13, 2012 /PRNewswire/ --The IP & Science business of Thomson Reuters,the world's leading source of intelligent information for businesses and professionals, today announced the publication of a new report that provides a comprehensive view of the potential effects of personalized medicine on drug research and development. Spotlight on Personalized Medicine, a Pharma Matters report based on insights and information from Thomson Reuters Cortellis for Competitive Intelligence and a selection of data from CMR International, details the current challenges posed by the paradigm of stratified medicine as well as its clinical, economic and societal value. "An array of scientific and market factors have prompted the pharma industry to question the sustainability of the current R&D model, which targets large populations with chronic unmet medical needs," said Jon Brett-Harris, executive vice president at Thomson Reuters. "Despite the commercial success of these products, the one-size-fits-all focus has resulted in spiraling R&D costs, longer development timelines and narrow product portfolios. New options, specifically personalized medicine, appear to be an attractive and more sustainable solution. This new report offers a detailed look into the possible advantages and disadvantages of this potentially game-changing approach." The report shows that a stratified paradigm could result in … Continue reading →

Regenerative Medicine Center, Reviva Lebanon. Our mission is to bring scientific innovation to patients seeking a trace of hope in new medicine therapy through cellular enhancement and medical excellence. We aim to be recognized as an all-in-one leader center in stem cell and regenerative medicine research and applications in the MENA region.From:revivamedicalViews:4 0ratingsTime:05:59More inPeople Blogs The rest is here: Regenerative Medicine Center, Reviva Lebanon. - Video … Continue reading →

Randall avoids knee replacement surgery after adult stem cell therapy by Dr Harry Adelson Randall describes his experience with adult stem cell therapy by Dr Harry Adelson on his arthritic knee and ankleFrom:Harry AdelsonViews:0 0ratingsTime:01:08More inScience Technology Visit link: Randall avoids knee replacement surgery after adult stem cell therapy by Dr Harry Adelson - Video … Continue reading →

A guide to Cryo-Save's stem cell collection and storage service http://www.cryo-save.com A brief overview of storing your baby's umbilical cord blood stem cells from start to finish. Learn about what happens after you order your kit, how samples are collected and processed for storage.From:CryoSaveWebmasterViews:0 0ratingsTime:03:19More inEducation Continue reading here: A guide to Cryo-Save's stem cell collection and storage service - Video … Continue reading →

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)-- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Brainstorm Cell Therapeutics Ltd. was awarded a 3 million NIS grant from Israels Office of the Chief Scientist (OCS) for the year 2013. The grant is intended to support BrainStorms Research and Development program for its innovative stem cell therapy candidate NurOwn. We are thankful to the OCS for its continued support of our Research and Development program. The non-dilutive capital funding from the OCS will help facilitate continuation of our clinical trials in Israel, as well as our preparations for clinical trials in the USA, said Dr. Adrian Harel, BrainStorms CEO. The OCS has supported BrainStorm Cell Therapeutics Ltd. since 2007, providing grants of a total of $1.8 million until today. The Company is required to pay royalties to the OCS, amounting to 3% - 3.5% of revenues derived from sales of the products funded with these grants, but only up to the amount equal to 100% of the grants received plus LIBOR interest. As reported by Brainstorm on Monday December 10, the Company anticipates announcing a new date for its shareholders teleconference … Continue reading →

MADISON, Wis., Dec. 12, 2012 /PRNewswire/ --Cellular Dynamics International (CDI), a leading commercial producer of human induced pluripotent stem cell (iPSC) lines and tissue cells, today announced the publication of research demonstrating the use of human iPSC-derived iCell Neurons to model Alzheimer's disease (AD) and how they may be used in high throughput drug screening. This research was performed by the lab of Zhong Zhong, Ph.D., head of discovery in the regenerative medicine group within GlaxoSmithKline (GSK), and recently published online in Stem Cell Research (DOI 10.1016/j.scr.2012.11.005). The GSK researchers used CDI's commercially available iCell Neurons, comprised of human neurons with characteristic forebrain markers, to model neuronal loss in human AD brains by exposing them to beta-amyloid 1-42 (AB1-42), a peptide known to be associated with AD. AB1-42 builds up in the brains of those susceptible to the disease and acts as a plaque that causes progressive memory loss and cognitive decline. Because iCell Neurons meet tight quality standards and are available commercially in large quantities, the researchers used this AD cellular model to screen hundreds of compounds and ultimately identified several small molecules that inhibited the AB1-42 toxicity. This is the first known use of human iPSCs to model … Continue reading →

Nano TMII promo video 121212 Nanomedicine Lab at Mount Sinai School of Medicine Translational and Molecular Imaging InstituteFrom:wjmmulderViews:0 2ratingsTime:04:25More inScience Technology Continued here: Nano TMII promo video 121212 - Video … Continue reading →

Video abstract Gold--stavudine--PLGA nanoparticles [38013] Video abstract of original research paper'Colloidal gold-loaded, biodegradable, polymer-based stavudine nanoparticle uptake by macrophages: an in vitro study' published in the International Journal of Nanomedicine by Basu S, Mukherjee B, Chowdhury SR, et al. Objective: We describe the development, evaluation, and comparison of colloidal gold-loaded, poly(d,l-lactic-co-glycolic acid)-based nanoparticles containing anti-acquired immunodeficiency syndrome drug stavudine and uptake of these nanoparticles by macrophages in vitro. Methods: We used the following methods in this study: drug-excipient interaction by Fourier transform infrared spectroscopy, morphology of nanoparticles by field-emission scanning electron microscopy, particle size by a particle size analyzer, and zeta potential and polydispersity index by a zetasizer. Drug loading and in vitro release were evaluated for formulations. The best formulation was incorporated with fluorescein isothiocyanate. Macrophage uptake of fluorescein isothiocyanate nanoparticles was studied in vitro. Results: Variations in process parameters, such as speed of homogenization and amount of excipients, affected drug loading and the polydispersity index. We found that the drug was released for a prolonged period (over 63 days) from the nanoparticles, and observed cellular uptake of stavudine nanoparticles by macrophages. Conclusion: Experimental nanoparticles represent an interesting carrier system for the transport of stavudine to ...From:dovepressViews:6 … Continue reading →